{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:22:54Z","timestamp":1784690574788,"version":"3.55.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T00:00:00Z","timestamp":1674345600000},"content-version":"am","delay-in-days":296,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI139261"],"award-info":[{"award-number":["R01AI139261"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Microbiology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.mib.2022.01.004","type":"journal-article","created":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T11:56:56Z","timestamp":1642852616000},"page":"63-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Mechanisms and impact of antimicrobial resistance in Clostridioides difficile"],"prefix":"10.1016","volume":"66","author":[{"given":"Chetna","family":"Dureja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2005-5706","authenticated-orcid":false,"given":"Abiola O","family":"Olaitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian G","family":"Hurdle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mib.2022.01.004_sbref0005","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/ciab718","article-title":"Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2022.01.004_sbref0010","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 6","key":"10.1016\/j.mib.2022.01.004_bib0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/1469-0691.12046","article-title":"Can we identify patients at high risk of recurrent Clostridium difficile infection?","volume":"18","author":"Kelly","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.mib.2022.01.004_bib0020","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMra1403772","article-title":"Clostridium difficile infection","volume":"372","author":"Leffler","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2022.01.004_bib0025","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1007\/s10096-021-04311-5","article-title":"Antimicrobial resistance in Clostridioides difficile","volume":"40","author":"O\u2019Grady","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.mib.2022.01.004_bib0030","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1093\/jac\/dkab231","article-title":"Mechanisms of antibiotic resistance of Clostridioides difficile","volume":"76","author":"Wickramage","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mib.2022.01.004_bib0035","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJM199911253412203","article-title":"Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals","volume":"341","author":"Johnson","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2022.01.004_bib0040","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01803-18","article-title":"Intrinsic class D beta-lactamases of Clostridium difficile","volume":"9","author":"Toth","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.mib.2022.01.004_bib0045","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01496-19","article-title":"Regulation and anaerobic function of the Clostridioides difficile beta-lactamase","volume":"64","author":"Sandhu","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2022.01.004_sbref0050","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3201\/eid2404.170095","article-title":"Imipenem resistance in Clostridium difficile ribotype 017, Portugal","volume":"24","author":"Isidro","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.mib.2022.01.004_bib0055","doi-asserted-by":"crossref","first-page":"45106","DOI":"10.1074\/jbc.M107608200","article-title":"Crystal structure of PBP2x from a highly penicillin-resistant Streptococcus pneumoniae clinical isolate: a mosaic framework containing 83 mutations","volume":"276","author":"Dessen","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.mib.2022.01.004_sbref0060","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/s41564-019-0519-1","article-title":"Cephamycins inhibit pathogen sporulation and effectively treat recurrent Clostridioides difficile infection","volume":"4","author":"Srikhanta","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.mib.2022.01.004_bib0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41564-019-0661-9","article-title":"Caution is warranted in using cephamycin antibiotics against recurrent Clostridioides difficile infection","volume":"5","author":"Wilcox","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.mib.2022.01.004_bib0070","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz013","article-title":"Epidemic Clostridioides difficile ribotype 027 lineages: comparisons of Texas versus worldwide strains","volume":"6","author":"Endres","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.mib.2022.01.004_bib0075","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ng.2478","article-title":"Emergence and global spread of epidemic healthcare-associated Clostridium difficile","volume":"45","author":"He","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.mib.2022.01.004_bib0080","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1128\/AAC.04503-14","article-title":"Fluoroquinolone resistance does not impose a cost on the fitness of Clostridium difficile in vitro","volume":"59","author":"Wasels","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2022.01.004_bib0085","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/jac\/dky535","article-title":"Effect of fluoroquinolone resistance mutation Thr-82-->Ile on Clostridioides difficile fitness","volume":"74","author":"Vernon","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mib.2022.01.004_bib0090","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1473-3099(16)30397-8","article-title":"Effect of a national 4C antibiotic stewardship intervention on the clinical and molecular epidemiology of Clostridium difficile infections in a region of Scotland: a non-linear time-series analysis","volume":"17","author":"Lawes","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.mib.2022.01.004_bib0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237987","article-title":"Evaluation of a successful fluoroquinolone restriction intervention among high-risk patients: a mixed-methods study","volume":"15","author":"Tischendorf","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.mib.2022.01.004_sbref0100","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00415-20","article-title":"Chromosomal resistance to metronidazole in Clostridioides difficile can be mediated by epistasis between iron homeostasis and oxidoreductases","volume":"64","author":"Deshpande","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2022.01.004_bib0105","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ijantimicag.2014.05.021","article-title":"Action of nitroheterocyclic drugs against Clostridium difficile","volume":"44","author":"Kumar","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mib.2022.01.004_bib0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053757","article-title":"Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolate","volume":"8","author":"Lynch","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.mib.2022.01.004_bib0115","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1128\/AAC.02350-14","article-title":"Multidisciplinary analysis of a nontoxigenic Clostridium difficile strain with stable resistance to metronidazole","volume":"58","author":"Moura","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2022.01.004_sbref0120","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1128\/JCM.00524-08","article-title":"Metronidazole resistance in Clostridium difficile is heterogeneous","volume":"46","author":"Pelaez","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mib.2022.01.004_sbref0125","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00585-21","article-title":"The integrity of heme is essential for reproducible detection of metronidazole-resistant Clostridioides difficile by agar dilution susceptibility tests","volume":"59","author":"Wu","year":"2021","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mib.2022.01.004_sbref0130","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/jac\/dkab097","article-title":"Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile","volume":"76","author":"Boekhoud","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mib.2022.01.004_sbref0135","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab365","article-title":"Reduced susceptibility to metronidazole is associated with initial clinical failure in Clostridioides difficile infection","volume":"8","author":"Gonzales-Luna","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.mib.2022.01.004_sbref0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-14382-1","article-title":"Plasmid-mediated metronidazole resistance in Clostridioides difficile","volume":"11","author":"Boekhoud","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.mib.2022.01.004_bib0145","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s40121-021-00426-6","article-title":"Global landscape of Clostridioides difficile phylogeography, antibiotic susceptibility, and toxin polymorphisms by post-hoc whole-genome sequencing from the MODIFY I\/II studies","volume":"10","author":"Zhao","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.mib.2022.01.004_bib0150","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1128\/AAC.41.7.1495","article-title":"Metabolism of a 5-nitroimidazole in susceptible and resistant isogenic strains of Bacteroides fragilis","volume":"41","author":"Carlier","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2022.01.004_bib0155","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/clinids\/22.5.813","article-title":"Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea","volume":"22","author":"Wenisch","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2022.01.004_bib0160","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","volume":"45","author":"Zar","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2022.01.004_bib0165","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1086\/506349","article-title":"Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea","volume":"43","author":"Louie","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2022.01.004_bib0170","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archinte.1986.00360180083015","article-title":"Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial","volume":"146","author":"Dudley","year":"1986","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.mib.2022.01.004_bib0175","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1128\/AAC.00845-15","article-title":"U.S.-based national sentinel surveillance study for the epidemiology of Clostridium difficile-associated diarrheal isolates and their susceptibility to fidaxomicin","volume":"59","author":"Snydman","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2022.01.004_bib0180","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jac\/dkn313","article-title":"Emergence of reduced susceptibility to metronidazole in Clostridium difficile","volume":"62","author":"Baines","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mib.2022.01.004_bib0185","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7040075","article-title":"Enhanced efficacy of high dose oral vancomycin therapy in Clostridium difficile diarrhea for hospitalized adults not responsive to conventional oral vancomycin therapy: antibiotic stewardship implications","volume":"7","author":"Cunha","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.mib.2022.01.004_sbref0190","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/jac\/dkz513","article-title":"Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates","volume":"75","author":"Shen","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mib.2022.01.004_sbref0195","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2018.01420","article-title":"Detection and investigation of eagle effect resistance to vancomycin in Clostridium difficile with an ATP-bioluminescence assay","volume":"9","author":"Jarrad","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.mib.2022.01.004_bib0200","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/cid\/ciz871","article-title":"Use of oral vancomycin for Clostridioides difficile infection and the risk of vancomycin-resistant enterococci","volume":"71","author":"Stevens","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2022.01.004_bib0205","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1089\/mdr.2017.0147","article-title":"Vancomycin-resistant enterococci: a review of antimicrobial resistance mechanisms and perspectives of human and animal health","volume":"24","author":"Ahmed","year":"2018","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.mib.2022.01.004_bib0210","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/ng1830","article-title":"The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome","volume":"38","author":"Sebaihia","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.mib.2022.01.004_bib0215","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/mmi.12299","article-title":"The functional vanGCd cluster of Clostridium difficile does not confer vancomycin resistance","volume":"89","author":"Ammam","year":"2013","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.mib.2022.01.004_bib0220","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00042-09","article-title":"Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications","volume":"23","author":"Howden","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.mib.2022.01.004_bib0225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/jac\/dkt302","article-title":"In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin","volume":"69","author":"Leeds","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mib.2022.01.004_bib0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002217","article-title":"c-di-AMP is a new second messenger in Staphylococcus aureus with a role in controlling cell size and envelope stress","volume":"7","author":"Corrigan","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.mib.2022.01.004_bib0235","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1128\/AAC.05148-11","article-title":"Loss of function of the GdpP protein leads to joint beta-lactam\/glycopeptide tolerance in Staphylococcus aureus","volume":"56","author":"Griffiths","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2022.01.004_sbref0240","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/j.gastro.2020.10.046","article-title":"Plasmid acquisition alters vancomycin susceptibility in Clostridioides difficile","volume":"160","author":"Pu","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mib.2022.01.004_bib0245","doi-asserted-by":"crossref","DOI":"10.1093\/femspd\/ftv114","article-title":"Subinhibitory concentrations of metronidazole increase biofilm formation in Clostridium difficile strains","volume":"74","author":"Vuotto","year":"2016","journal-title":"Pathog Dis"},{"key":"10.1016\/j.mib.2022.01.004_bib0250","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4161\/gmic.25862","article-title":"Biofilm formation by Clostridium difficile","volume":"4","author":"Dapa","year":"2013","journal-title":"Gut Microbes"},{"key":"10.1016\/j.mib.2022.01.004_bib0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087757","article-title":"Spore formation and toxin production in Clostridium difficile biofilms","volume":"9","author":"Semenyuk","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.mib.2022.01.004_bib0260","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.molcel.2018.02.026","article-title":"Structural basis of transcription inhibition by fidaxomicin (Lipiarmycin A3)","volume":"70","author":"Lin","year":"2018","journal-title":"Mol Cell"},{"key":"10.1016\/j.mib.2022.01.004_bib0265","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1128\/AAC.00625-11","article-title":"Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection","volume":"55","author":"Goldstein","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2022.01.004_bib0270","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1099\/jmm.0.029470-0","article-title":"Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile","volume":"60","author":"Babakhani","year":"2011","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.mib.2022.01.004_bib0275","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1128\/AAC.02572-13","article-title":"Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile","volume":"58","author":"Babakhani","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2022.01.004_sbref0280","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/jac\/dkx486","article-title":"Characterization of the impact of rpoB mutations on the in vitro and in vivo competitive fitness of Clostridium difficile and susceptibility to fidaxomicin","volume":"73","author":"Kuehne","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mib.2022.01.004_bib0285","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jac\/dky375","article-title":"Characterization of a clinical Clostridioides difficile isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in rpoB","volume":"74","author":"Schwanbeck","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mib.2022.01.004_bib0290","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2022.01.004_bib0295","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1128\/AAC.48.12.4898-4902.2004","article-title":"In vitro activities of OPT-80 and comparator drugs against intestinal bacteria","volume":"48","author":"Finegold","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2022.01.004_bib0300","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1128\/AAC.00398-11","article-title":"Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3","volume":"55","author":"Matsuo","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2022.01.004_bib0305","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00550-17","article-title":"Convergent evolution driven by rifampin exacerbates the global burden of drug-resistant Staphylococcus aureus","volume":"3","author":"Guerillot","year":"2018","journal-title":"mSphere"},{"key":"10.1016\/j.mib.2022.01.004_sbref0310","doi-asserted-by":"crossref","first-page":"5604","DOI":"10.1128\/AAC.01137-16","article-title":"Rifamycin resistance in Clostridium difficile is generally associated with a low fitness burden","volume":"60","author":"Dang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2022.01.004_bib0315","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.anaerobe.2018.10.011","article-title":"A systematic review of the use of rifaximin for Clostridium difficile infections","volume":"55","author":"Ng","year":"2019","journal-title":"Anaerobe"},{"key":"10.1016\/j.mib.2022.01.004_bib0320","doi-asserted-by":"crossref","DOI":"10.1186\/s13756-020-00815-5","article-title":"Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis","volume":"9","author":"Sholeh","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.mib.2022.01.004_bib0325","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1128\/AAC.02465-15","article-title":"Potential of tetracycline resistance proteins to evolve tigecycline resistance","volume":"60","author":"Linkevicius","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2022.01.004_bib0330","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-020-0966-5","article-title":"Tetracycline-inactivating enzymes from environmental, human commensal, and pathogenic bacteria cause broad-spectrum tetracycline resistance","volume":"3","author":"Gasparrini","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.mib.2022.01.004_bib0335","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1128\/AAC.00974-12","article-title":"In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy","volume":"56","author":"Carman","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2022.01.004_sbref0340","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02790-18","article-title":"A role for tetracycline selection in recent evolution of agriculture-associated Clostridium difficile PCR ribotype 078","volume":"10","author":"Dingle","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.mib.2022.01.004_bib0345","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1128\/JB.01980-12","article-title":"Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile","volume":"195","author":"Ethapa","year":"2013","journal-title":"J Bacteriol"},{"key":"10.1016\/j.mib.2022.01.004_bib0350","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10155-x","article-title":"CD2068 potentially mediates multidrug efflux in Clostridium difficile","volume":"7","author":"Ngernsombat","year":"2017","journal-title":"Sci Rep"}],"container-title":["Current Opinion in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527422000108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527422000108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:54:27Z","timestamp":1761285267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1369527422000108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":70,"alternative-id":["S1369527422000108"],"URL":"https:\/\/doi.org\/10.1016\/j.mib.2022.01.004","relation":{},"ISSN":["1369-5274"],"issn-type":[{"value":"1369-5274","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms and impact of antimicrobial resistance in Clostridioides difficile","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mib.2022.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}